Pcn145 - Cost-Effectiveness of Nintedanib for the Treatment of Non-Small Lung Cancer in Portugal

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.228
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Cost Effectiveness of Treatment With New Agents in Advanced Non-Small-Cell Lung Cancer

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2012English

Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Pcn152 - Cost Effectiveness of Alectinib in the First Line Treatment of Advanced Alk-Positive Non-Small Cell Lung Cancer in Turkey

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Cost of Cancer Treatment in Portugal

ecancermedicalscience
Cancer ResearchOncology
2017English

Pcn140 - Cost-Effectiveness Analysis of Alectinib vs Crizotinib in First Line Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Effectiveness of Palliative Care for Non-Small Cell Lung Cancer

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2016English

A Systematic Review of the Cost-Effectiveness of Targeted Therapies for Metastatic Non-Small Cell Lung Cancer (NSCLC)

BMC Pulmonary Medicine
PulmonaryRespiratory Medicine
2014English

Gefitinib for the Treatment of Non-Small-Cell Lung Cancer

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2010English

Comparative Effectiveness of Five Treatment Strategies for Early-Stage Non-Small Cell Lung Cancer in the Elderly.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy